公开(公告)号：US20240115515A1

公开(公告)日：2024-04-11

申请号：US18166782

申请日：2023-02-09

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Dae-Ro AHN ,  Kyoung-Ran KIM ,  Junghyun KIM ,  Ji Eun LEE ,  Ji hyun BACK

IPC: A61K9/51 ,  A61K47/54 ,  A61P1/16 ,  C12N15/113

CPC classification number: A61K9/5169 ,  A61K47/549 ,  A61P1/16 ,  C12N15/113

Abstract: The present invention relates to a liver-specific drug delivery carrier comprising a nucleic acid nanoparticle and cholesterol; a liver-specific complex; a pharmaceutical composition for prevention or treatment of liver disease using the same; and a method for preventing or treating liver disease.

公开(公告)号：US20160287706A1

公开(公告)日：2016-10-06

申请号：US14514855

申请日：2014-10-15

Applicant: Korea Institute of Science and Technology

Inventor： Dae-Ro AHN

IPC: A61K47/26 ,  A61K31/704 ,  A61K38/16 ,  A61K31/7088

CPC classification number: A61K31/704 ,  A61K9/5146 ,  A61K31/7088 ,  A61K38/00

Abstract: The present invention relates to a drug carrier having L-DNA nanocage structure prepared by using L-DNA, the mirror form of natural DNA, as a backbone. The drug carrier of the present invention has very superior cellular uptake efficiency and serum stability, so that it can be applied to deliver various drugs into cells usefully.

Abstract translation: 本发明涉及一种使用L-DNA（天然DNA的镜像形式）作为骨架制备的具有L-DNA纳米结构结构的药物载体。 本发明的药物载体具有非常优异的细胞摄取效率和血清稳定性，因此可用于将各种药物有效地递送到细胞中。

公开(公告)号：US20220090065A1

公开(公告)日：2022-03-24

申请号：US17464691

申请日：2021-09-02

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Dae-Ro AHN ,  Jihyun PARK ,  Hak Suk CHUNG ,  Cherlhyun JEONG

IPC: C12N15/11 ,  C12N9/22

Abstract: The present invention relates to a novel trans-activating CRISPR RNA (tracrRNA) including a fragment of a tracrRNA, and a gRNA, a CRISPR-Cas9 system, and a kit including the tracrRNA.

公开(公告)号：US20210130831A1

公开(公告)日：2021-05-06

申请号：US17084906

申请日：2020-10-30

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Dae-Ro AHN ,  Junghyun KIM ,  Seong Jae KANG

IPC: C12N15/113 ,  A61K47/64 ,  A61P11/00

Abstract: The present invention relates to a lung-specific drug delivery system consisting of oligonucleotide polymers and biocompatible cationic peptides for the prevention or treatment of pulmonary fibrosis, and a use thereof. The drug delivery system according to the present invention can be specifically accumulated in the lungs and absorbed into lung fibrotic cells to knock down TGF-β, thereby preventing or treating pulmonary fibrosis.

公开(公告)号：US20210128748A1

公开(公告)日：2021-05-06

申请号：US17085089

申请日：2020-10-30

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Dae-Ro AHN ,  Thai Bao Dieu Hien

IPC: A61K47/69 ,  A61K47/56 ,  A61K31/7105 ,  C12N15/113 ,  A61P13/12

Abstract: The present invention relates to three-dimensional self-assembled nucleic acid nanoparticles, a drug delivery system comprising the same, and a pharmaceutical composition for the prevention or treatment of acute kidney injury, which comprises the same. The three-dimensional self-assembled nucleic acid nanoparticles of the present invention, which have a tetrahedral structure, exhibit an excellent renal-targeting ability, and thus the nanoparticles conjugated with the pharmaceutically active ingredient for p53 exhibit excellent p53 and caspase 3 expression reductions in vitro and in vivo, and can thereby be applied to the prevention or treatment of acute kidney injury.